https://industryfocusswitzerland.com/article/915712307-crispr-therapeutics-to-participate-in-upcoming-investor-conferences Industry Focus Switzerland en PressRelease 2026-05-28T12:00:00+00:00 CRISPR Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/5dac7d0d-131d-4047-bab7-db8e0719bf58/small/crispr-logo-jpg.jpg https://industryfocusswitzerland.com/article/915668850-stellar-alpina-raises-chf-3-5m-to-build-detonation-based-propulsion-for-mobility-after-launch Industry Focus Switzerland en PressRelease 2026-05-28T08:00:00+00:00 Stellar Alpina Raises CHF 3.5M to Build Detonation-Based Propulsion for Mobility After Launch https://ml-eu.globenewswire.com/media/b6c0b70b-ebb6-45da-aec0-867b82e6cd21/medium/the-founders-of-stellar-alpina.jpeg https://industryfocusswitzerland.com/article/915668861-anaveon-reports-clinical-benefit-of-anv600-in-the-expand-1-phase-1-clinical-trial-at-asco-2026-and-actively-seeks-partners-for-its-legacy-oncology Industry Focus Switzerland en PressRelease 2026-05-28T08:00:00+00:00 Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio https://ml.globenewswire.com/media/376f71da-1a19-4a9a-bb0a-5d12feb63780/small/logo-anaveon-jpg.jpg https://industryfocusswitzerland.com/article/915632078-basilea-erh-lt-weitere-usd-13-mio-von-barda-zur-entwicklung-des-neuartigen-antibiotikums-ceftibuten-ledaborbactam Industry Focus Switzerland en PressRelease 2026-05-28T05:15:00+00:00 Basilea erhält weitere USD 13 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam https://ml-eu.globenewswire.com/media/4403c5ae-6c9a-43d2-8c5f-deb2de747a47/small/basilea-logo-jpg.jpg https://industryfocusswitzerland.com/article/915632120-basilea-receives-further-usd-13-million-from-barda-to-continue-development-of-novel-antibiotic-ceftibuten-ledaborbactam Industry Focus Switzerland en PressRelease 2026-05-28T05:15:00+00:00 Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam https://ml-eu.globenewswire.com/media/4403c5ae-6c9a-43d2-8c5f-deb2de747a47/small/basilea-logo-jpg.jpg https://industryfocusswitzerland.com/article/914973251-revieve-und-die-matas-group-starten-eine-nordische-partnerschaft-zur-skalierung-ki-gest-tzter-beauty-erlebnisse Industry Focus Switzerland en PressRelease 2026-05-27T12:00:00+00:00 Revieve und die Matas Group starten eine nordische Partnerschaft zur Skalierung KI-gestützter Beauty-Erlebnisse https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24866352-matas-revieve-1920x1080.png https://industryfocusswitzerland.com/article/915373175-ivybears-emerges-as-breakout-new-animation-ip-with-15m-youtube-views-and-1-9m-trailer-views-ahead-of-episode-two Industry Focus Switzerland en PressRelease 2026-05-27T11:44:24+00:00 IvyBears Emerges as Breakout New Animation IP With 15M+ YouTube Views and 1.9M Trailer Views Ahead of Episode Two https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24868214-ivybears-2912x1632.png https://industryfocusswitzerland.com/article/914352754-kunobi-desktop-launches-to-bring-operational-clarity-to-kubernetes-and-gitops-teams Industry Focus Switzerland en PressRelease 2026-05-27T07:00:00+00:00 Kunobi Desktop Launches to Bring Operational Clarity to Kubernetes and GitOps Teams https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24866881-kunobi-v1-release-announcement-1184x675.png https://industryfocusswitzerland.com/article/915446182-hashdex-continues-to-bolster-u-s-presence-with-key-senior-sales-team-hires Industry Focus Switzerland en PressRelease 2026-05-27T13:00:00+00:00 Hashdex Continues to Bolster U.S. Presence With Key Senior Sales Team Hires https://ml-eu.globenewswire.com/media/036f46b4-9065-4cdc-ac61-4a756ec466f8/small/property-1-default-2x-480-png.png https://industryfocusswitzerland.com/article/915433775-newcelx-ltd-submits-pre-ind-package-to-the-fda-for-ncel-101-for-the-treatment-of-type-1-diabetes Industry Focus Switzerland en PressRelease 2026-05-27T11:55:00+00:00 NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes https://ml.globenewswire.com/media/ac801d4e-6ea5-4452-87c2-aa6a05bec73c/small/logo-positive-2x-jpg.jpg https://industryfocusswitzerland.com/article/915420224-statement-from-the-supervisory-board-of-stmicroelectronics Industry Focus Switzerland en PressRelease 2026-05-27T10:50:00+00:00 Statement from the Supervisory Board of STMicroelectronics https://ml-eu.globenewswire.com/media/281fbc38-04be-49ef-832b-48f4f2f8c959/small/st-logo-2024-blue-jpg.jpg https://industryfocusswitzerland.com/article/915420229-d-claration-du-conseil-de-surveillance-de-stmicroelectronics Industry Focus Switzerland en PressRelease 2026-05-27T10:50:00+00:00 Déclaration du Conseil de Surveillance de STMicroelectronics https://ml-eu.globenewswire.com/media/281fbc38-04be-49ef-832b-48f4f2f8c959/small/ https://industryfocusswitzerland.com/article/915420203-all-resolutions-approved-at-the-2026-stmicroelectronics-annual-general-meeting-of-shareholders Industry Focus Switzerland en PressRelease 2026-05-27T10:40:00+00:00 All resolutions approved at the 2026 STMicroelectronics’ Annual General Meeting of Shareholders https://ml-eu.globenewswire.com/media/281fbc38-04be-49ef-832b-48f4f2f8c959/small/st-logo-2024-blue-jpg.jpg https://industryfocusswitzerland.com/article/915420206-approbation-de-toutes-les-r-solutions-l-assembl-e-g-n-rale-annuelle-des-actionnaires-2026-de-stmicroelectronics Industry Focus Switzerland en PressRelease 2026-05-27T10:40:00+00:00 Approbation de toutes les résolutions à l’Assemblée Générale Annuelle des Actionnaires 2026 de STMicroelectronics https://ml-eu.globenewswire.com/media/281fbc38-04be-49ef-832b-48f4f2f8c959/small/ https://industryfocusswitzerland.com/article/915395575-nuclidium-announces-closing-of-series-b-extension-bringing-total-round-to-chf-105-million Industry Focus Switzerland en PressRelease 2026-05-27T09:00:00+00:00 NUCLIDIUM Announces Closing of Series B Extension Bringing Total Round to CHF 105 Million https://ml-eu.globenewswire.com/media/1d4d34a4-57ec-416b-b58f-06af370ce718/small/nuclidium-logo-1-png.png